Evidence map›Paper›PMID 35571565›Full record

ArticleJournal of immunology research2022

Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.

Li Shan, Ye Lu, Cheng-Cheng Xiang, Xiaoli Zhu, Er-Dong Zuo, Xu Cheng

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Non-coding RNA-Mediated N6-Methyladenosine (mNon-coding RNA research · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Li ShanDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.ORCID https://orcid.org/0000-0001-5882-2240
Ye LuDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.ORCID https://orcid.org/0000-0001-9337-8333
Cheng-Cheng XiangDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.
Xiaoli ZhuDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.
Er-Dong ZuoDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.
Xu ChengDepartment of Oncology, Soochow University Affiliated Taicang Hospital (The First People's Hospital of Taicang), Jiangsu 215400, China.ORCID https://orcid.org/0000-0001-5611-4689
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Due to difficulties involved in its early diagnosis and adequate prognostication, uterine corpus endometrial carcinoma (UCEC) is one of the most serious threats to human health, with the five-year survival rate being as low as roughly 60%. The discovery of specific biomarkers that serve as prognosticators of UCEC is of great significance. The role of N6-methyladenosine- (m6A-) related long noncoding RNAs (lncRNAs) in the pathogenesis of UCEC remains undefined. In this study, we explored the expression profiles of m6A-related lncRNAs of patients with UCEC and identified novel prognostic markers for UCEC. Methods: Gene expression and clinical data were extracted from The Cancer Genome Atlas. Coexpression analysis was performed to identify m6A-related lncRNAs, which were entered into univariate Cox regression models for evaluating the prognosis of UCEC. Clusters of UCEC patients and enrichment pathways were identified using consistent data clustering and gene set enrichment analysis (GSEA). A risk score model was established, and Kaplan-Meier analysis was conducted for investigating overall survival (OS) across two patient groups (high risk and low risk). Lastly, the relationship between the risk score and the cell content of 22 types of immune cells, clusters, age, programmed cell death 1 ligand-1 (PD-L1) expression level, immune score, and pathological grade was analyzed. Results: We identified a total of 2084 lncRNAs associated with m6A, of which 32 lncRNAs were prognostically relevant. Two clusters (clusters 1 and 2) of patients with UCEC were defined; patients in cluster 1 were found to have significantly higher pathological grades and shorter overall survival time compared to those in cluster 2. GSEA showed that "MITOTIC SPINDLE and other pathways" were more enriched in cluster 1. Five major lncRNAs associated with m6A were screened out, and risk score modeling was used for UCEC prognosis prediction. High risk scores were associated with a shorter OS. The risk score was also verified as an independent prognostic indicator for UCEC and was related to immune cell infiltration levels. Finally, we observed a higher pathological grade and greater levels of PD-L1 in the high-risk group than in the low-risk group of patients. Conclusions: m6A-related lncRNAs play an important role in UCEC progression. The risk-based model constructed from the five key m6A-related lncRNAs was implicated in immune cell infiltration and can potentially be an accurate prognosticator for UCEC.

Indexed as

Endometrial NeoplasmsRNA, Long NoncodingB7-H1 AntigenBiomarkers, TumorFemaleHumansPrognosisB7-H1 AntigenBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID35571565
PMCPMC9095403
OpenAlexW4229046595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.